The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients

Surgical Infections

Volumn 10, Issue 6, 2009, Pages 563-570

  Mueller, Eric W ^a   Boucher, Bradley A ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; GENTAMICIN; TOBRAMYCIN;

AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HOST; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NOMOGRAM; PLASMA CLEARANCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SURGICAL INFECTION; SURGICAL PATIENT; TIME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; HUMANS;

EID: 73849122729     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2007.080     Document Type: Article

References (83)

1. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-1133.
2. Craig WA, Andes D. Aminoglycosides are useful for severe respiratory tract infections. Semin Respir Infect. 1997;12:271-277.
3. Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg Infect (Larchmt). 2002;3:315-335.
4. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect (Larchmt) 2002;3:161-173.
5. Anonymous. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1995;153:1711-1725.
6. Chastre J, Fagon J-Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165:867-903.
7. Luchette FA, Bone LB, Born CT, et al. Eastern Association for the Surgery of Trauma Practice Management Guidelines Work Group: Practice management guidelines for prophylactic antibiotic use in open fractures. http:==www.east .org=tpg=openfrac.pdf. Accessed January 24, 2004.
8. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32:1249-1272.
9. DiPiro JT, Edmiston CE, Bohnen JMA. Pharmacodynamics of antimicrobial therapy in surgery.AmJ Surg 1996;171:615-622.
10. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing in mice and men. Clin Infect Dis 1998;26:1-12.
11. Lacy MK, Nicolau DP, Nightingale CH, et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998;27:23-27.
12. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32 (suppl 1):S39-S46.
13. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999;37:1-16.
14. Watling SM, Dasta JF. Aminoglycoside dosing considerations in intensive care unit patients. Ann Pharmacother 1993;27:351-357.
15. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549-1555.
16. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:796-809.
17. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997;24:786-795.
18. Dager WE. Aminoglycoside pharmacokinetics: Volume of distribution in specific adult patient populations. Ann Pharmacother 1994;28:944-951.
19. Begg EJ, Peddie BA, Chambers ST, et al. Comparison of gentamicin dosing regimens using an in vitro model. J Antimicrob Chemother 1992;29:427-433.
20. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: Application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-326.
21. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-99.
22. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J infect Dis 1984;149:443-448.
23. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984;77:657-662.
24. Kashuba ADM, Nafzinger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999;43:623-629.
25. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, ed. Antibiotics in laboratory medicine. 4th ed. Baltimore: Williams and Wilkins, 1996:296-329.
26. Odenholt I. Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents 2001;17:1-8.
27. McCormack JP, Jewesson PJ. A critical reevaluation of the ''therapeutic range'' of aminoglycosides. Clin Infect Dis 1992;14:320-339.
28. Humes HD, Weinberg JM, Knauss TC. Clinical and pathophysiologic aspects of aminoglycoside nephrotoxicity. Am J Kidney Dis 1982;2:5-29.
29. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986;77: 1492-1500.
30. DeBroe ME, Paulus GJ, Verpooten GA. Early effects of gentamicin, tobramycin, and amikacin on the human kidney. Kidney Int 1984;25:643-652.
31. Verpooten GA, Giuliano RA, Verbist L, et al. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22-27.
32. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother 1991;35:117-123.
33. Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: Importance for effective dosage regimens. Drugs 2001;61: 713-721.
34. Gilbert DN. Editorial response: Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. Clin Infect Dis 1997;24:816-819.
35. Chuck SK, Raber SR, Rodvold KA, et al. National survey of extended-interval aminoglycoside dosing. Clin Infect Dis 2000;30:433-439.
36. Schumock GT, Raber SR, Crawford SY, et al. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacother 1995;15:201-209.
37. NicolauDP, Freeman CD, Belliveau PP, et al. Experiencewith a once-daily aminoglycoside program administered to 2,184 adult patients.AntimicrobAgents Chemother 1995;39:650-655.
38. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice. J Antimicrob Chemother 1997;39:677-686.
39. Bertino JS, Rotschafer JC. Editorial response: Single daily dosing of aminoglycosides-a concept whose time has not yet come. Clin Infect Dis 1997;24:820-823.
40. Galloe AM, Graudal N, Christensen HR, et al. Aminoglycosides: Single or multiple daily dosing? A meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995;48:39-43.
41. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: An examination of meta-analysis with an emphasis on oncedaily aminoglycoside comparative trials. Pharmacother 1996;16:1093-1102.
42. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis. Am J Health Syst Pharm 1996;53:1141-1150.
43. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis. Ann Intern Med 1996;124:717-725.
44. Barza M, Ioannidis JPA, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: A meta-analysis. BMJ 1996;312:338-345. (Pubitemid 26049400)
45. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996;37:645-663.
46. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacother 1999;19:1252-1260.
47. Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: Quantitative relationships. Clin Pharmacokinet 2003;42:493-500.
48. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988;16:327-330.
49. Boucher BA, Coffey, BC, Kuhl DA, et al. Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides. Am J Surg 1990;160:473-480.
50. Singri N, Ahya SN, Levin ML. Acute renal failure. JAMA 2003;289:747-751.
51. Pruchnicki MC, Dasta JF. Acute renal failure in hospitalized patients: Part I. Ann Pharmacother 2002;36:1261-1267.
52. Kashuba ADM, Bertino JS, Nafzinger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother 1998;42:1842-1844.
53. Marik PE. Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993;21:172-173.
54. Ericsson CD, Fischer RP, Rowlands BJ, et al. Prophylactic antibiotics in trauma: The hazards of underdosing. J Trauma 1989;29:1356-1361.
55. Zaske DE, Cipolle RJ, Strate RJ. Gentamicin dosage requirements: Wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980;87:164-169.
56. Perkins MW, Dasta JF, DeHaven B. Physiologic implications of mechanical ventilation on pharmacokinetics. DICP Ann Pharmacother 1989;23:316-323.
57. Mann HJ, Fuhs DW, Awang R, et al. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1989;6:148-153.
58. Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002;28:936-942.
59. Chelluri L, Jastremski MS. Inadequacy of standard aminoglycoside loading doses in acutely ill patients. Crit Care Med 1987;15:1143-1145.
60. Niemiec PW, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987;122:207-212.
61. Sangha KS, Miyagawa CI, Healy DP, et al. Pharmacokinetics of once-daily dosing of gentamicin in surgical intensive care unit patients with open fractures. Ann Pharmacother 1995; 29:117-119.
62. Oparaoji EC, Siram S, Shoheiber O, et al. Appropriateness of a 4mg=kg gentamicin or tobramycin loading dose in postoperative septic shock patients. J Clin Pharm Ther 1998;23: 185-190.
63. Chelluri L, Warren J, Jastremski MS. Pharmacokinetics of a 3mg=kg body weight loading dose of gentamicin or tobramycin in critically ill patients. Chest 1989;95:1295-1297.
64. Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997;25:806-811.
65. Dorman T, Swoboda S, Zarfeshenfard F, et al. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Surgery 1998;124:73-78.
66. Mann HJ, Wittbrodt ET, Baghaie AA, et al. Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients. Pharmacother 1998;18:371-378.
67. Lewis DR, Longman RJ, Wisheart JD, et al. The pharmacokinetics of a single dose of gentamicin (4mg=kg) as prophylaxis in cardiac surgery requiring cardiopulmonary bypass. Cardiovasc Surg 1999;7:398-401.
68. Cornwell EE, Belzberg H, Berne TV, et al. Aminoglycoside levels in critically ill surgical patients: The implications of physiologic criteria of sepsis. South Med J 1997;90:33-36.
69. Townsend PL, Fink MP, Stein KL, et al. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989;17:154-157.
70. Hoey LL, Tschida SJ, Rotschafer JC, et al. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 1997;18:116-124.
71. Finnell DL, Davis GA, Cropp CD, et al. Validation of the Hartford Nomogram in trauma surgery patients. Ann Pharmacother 1998;32:417-420.
72. Kluth V, Koch S, Song M. Alternative aminoglycoside dosing in neurointensive care unit patients. Crit Care Med 1998; 26 (suppl 1):99A.
73. Wolfe TA, Dasta JF, Reilley TE, et al. Assessment of the appropriateness of once-daily aminoglycoside dosing in surgical intensive care unit patients. Crit Care Med 1998;26 (suppl 1):99A.
74. Brusco L, Talbert S, Wedderburn RV. Once-daily aminoglycoside dosing protocol results in inadequate gentamicin levels in surgical intensive care unit patients with normal renal function. Crit Care Med 1999;27 (suppl 1):138A.
75. Dwivedi A, Jucha J, Czerwinski C, et al. Once daily aminoglycoside dosing (7mg=kg) in surgical ICU patients fails to achieve therapeutic target peak levels. Crit Care Med 1999;27 (suppl 1):138A.
76. Barletta JF, Johnson SB, Nix DE, et al. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma 2000;49:869-872.
77. Wallace AW, Jones M, Bertino JS. Evaluation of four oncedaily aminoglycoside nomograms. Pharmacother 2002;22: 1077-1083.
78. Toschlog EA, Blount KP, Rotondo MF, et al. Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing. J Trauma 2003;55: 255-262.
79. Bracco D, Landry C, Dubois MJ, Effimann P. Pharmacokinetic variability of extended-interval tobramycin in burn patients. Burns 2008;34:791-796.
80. Chambers HF, Sande MA. The Aminoglycosides. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman and Gillman's The Pharmacological Basis of Therapeutics. New York. McGraw-Hill 1996:1103-1120.
81. Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128:545-552.
82. Muller M. Microdialysis. BMJ 2002;324:588-591.
83. Wood GC, Swanson JM. Aerosolized antimicrobials for the prevention and treatment of hospital-acquired pneumonia. Drugs 2007;67:903-914.